In The Know-August 2023

August 2023

Pdf Summary

1. CAR T-cell therapy effectively controlled ovarian cancer in a mouse model by activating the immune system and killing tumor cells.<br />2. CAR-T cells with high affinity for tumor antigen showed promise in controlling ovarian tumor growth in mice.<br />3. PARP inhibitors could be effective in treating SF3B1 mutant cancers.<br />4. Patients treated by female surgeons had lower risk-adjusted likelihood of adverse postoperative outcomes.<br />5. A six-protein classifier could potentially predict chemoresistance in high-grade serous ovarian carcinoma patients.<br />6. Targeted and immune-based approaches are being explored for the treatment of ovarian cancer.<br />7. BRCA1 promoter methylation testing predicted better response to PARP inhibitor treatment in ovarian cancer patients.<br />8. Combination of ATR and PARP inhibitors showed activity in PARP inhibitor-resistant ovarian cancer patients.<br />9. Molecular testing is a cost-effective approach to diagnose endometrial cancer in women with postmenopausal bleeding.<br />10. Lymph node characteristics were predictive factors for survival in elderly stage III serous ovarian cancer patients.<br />11. IMRT reduced toxicities compared to 3D-CRT in cervical cancer patients undergoing radiation therapy.<br />12. Temozolomide sensitizes ARID1A-mutated ovarian cancers to PARP inhibitors.<br />13. Discontinuation of bevacizumab treatment increased the risk of tumor progression in ovarian cancer patients.<br /><br />Further reading:<br />- Gynecologic Oncology: Table of Contents.

Keywords

CAR T-cell therapy

ovarian cancer

mouse model

immune system activation

tumor cell killing

PARP inhibitors

chemoresistance prediction

BRCA1 promoter methylation testing

lymph node characteristics

radiation therapy